Pyoderma Gangrenosum Associated With Inflammatory Bowel Disease. Report of Two Cases With Good Response to Infliximab

Cubero, Carmen Carrasco; Tudela, M. Mar Ruiz; Maestrojuan, José Javier Salaberri; Venegas, José Javier Pérez

doi:10.1016/j.reumae.2011.07.006

Cited by 4 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten required a second‐line therapy, with nine responding. Of the nine, six had infliximab . Of the other three, two required the addition of topical tacrolimus or mesalazine to oral steroids.…”

Section: Resultsmentioning

confidence: 99%

“…In 25 patients on some IBD therapy, 16 had active IBD at PG onset. Nine were initially on only 5‐ASA; all received first‐line therapy with systemic steroid, three in combination with AZA and one with ciclosporin . Only one case responded to systemic steroids; others required second‐line therapy with infliximab ( n = 7), topical human recombinant epidermal growth factor ( n = 1) or topical tacrolimus + AZA ( n = 1) …”

Section: Resultsmentioning

confidence: 99%

“…Of the nine, six had infliximab. 14,17,[25][26][27][28] Of the other three, two required the addition of topical tacrolimus 11 or mesalazine 29 to oral steroids. The third had stoma closure after combination therapy of ciclosporin + mesalazine + topical steroids.…”

Section: Case Series From Literature Post 2003mentioning

confidence: 99%

“…Nine were initially on only 5-ASA; all received first-line therapy with systemic steroid, 19,25,[32][33][34] three in combination with AZA 35,36 and one with ciclosporin. 33 Only one case responded to systemic steroids 32 ; others required second-line therapy with infliximab (n = 7), 19,25,33,35,36 topical human recombinant epidermal growth factor (n = 1) 34 or topical tacrolimus + AZA (n = 1). 37 Three were on 5-ASA and steroids at PG onset, two did not respond to increased steroid dose as first-line therapy, but responded to second-line therapy with leucocytapheresis (n = 1) 38 or infliximab (n = 1).…”

Section: Case Series From Literature Post 2003mentioning

confidence: 99%

See 3 more Smart Citations

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Agarwal

Andrews

2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Case Series From Literature Post 2003mentioning

confidence: 99%

Section: Case Series From Literature Post 2003mentioning

confidence: 99%

See 2 more Smart Citations

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Agarwal

Andrews

2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…78 In steroid-refractory PG, especially when associated with IBD (particularly CD), TNF-a inhibitors, particularly infliximab, may also have a role as a steroid-sparing agent. PG can respond to the basic treatment of IBD, but its relationship with disease activity is less obvious than in other mucocutaneous EIMs, such as erythema nodosum (EN) 79 ; indeed, about 30% of patients with PG do not experience improvement of their lesions with treatment of the underlying IBD. 80 …”

Section: Pyoderma Gangrenosummentioning

confidence: 99%

Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases

Marzano

Borghi

Stadnicki

et al. 2014

Inflammatory Bowel Diseases

120

View full text Add to dashboard Cite

The skin is one of the most common extraintestinal organ system affected in patients with inflammatory bowel disease (IBD), including both Crohn's disease and ulcerative colitis. The skin manifestations associated with IBD are polymorphic and can be classified into 4 categories according to their pathophysiology: (1) specific, (2) reactive, (3) associated, and (4) induced by IBD treatment. Cutaneous manifestations are regarded as specific if they share with IBD the same granulomatous histopathological pattern: perianal or metastatic Crohn's disease (commonly presenting with abscesses, fistulas or hidradenitis suppurativa-like features) is the prototype of this setting. Reactive cutaneous manifestations are different from IBD in the histopathology but have close physiopathological links: pyoderma gangrenosum, a neutrophil-mediated autoinflammatory skin disease typically manifesting as painful ulcers, is the paradigm of this group. Among the cutaneous diseases associated with IBD, the most commonly seen are erythema nodosum, a form of panniculitis most commonly involving bilateral pretibial areas, and psoriasis, a T helper 1/T helper 17-mediated erythematous squamous inflammatory disease. Finally, the number of cutaneous adverse reactions because of IBD therapies is progressively increasing. The most frequent drug-induced cutaneous manifestations are psoriasis-like, eczema-like, and lichenoid eruptions, as well as cutaneous lupus erythematosus for biologics, and nonmelanoma skin cancer, mainly basal cell and squamous cell carcinomas for thiopurines.

show abstract

Pyoderma gangrenosum and chronic granulomatous disease treated with adalimumab: Case-based review

Tharwat

Ahmed

2021

The Egyptian Rheumatologist

View full text Add to dashboard Cite

Pyoderma Gangrenosum Associated With Inflammatory Bowel Disease. Report of Two Cases With Good Response to Infliximab

Cited by 4 publications

References 6 publications

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases

Pyoderma gangrenosum and chronic granulomatous disease treated with adalimumab: Case-based review

Contact Info

Product

Resources

About